Acer Therapeutics Competitors, Revenue and Alternatives

Claim your profile


Boston, MA USA
Total Funding:$29M
Lead Investor(s):William Blair & Company, L.L.C.
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Acer Therapeutics's estimated annual revenue is currently $5M per year.
  • Acer Therapeutics received $11.0M in venture funding in December 2017.
  • Acer Therapeutics's estimated revenue per employee is $122,561
  • Acer Therapeutics's total funding is $29M.

Employee Data

  • Acer Therapeutics has 41 Employees.
  • Acer Therapeutics grew their employee count by 21% last year.
  • Acer Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ironwood Pharma...
Infinity Pharma...
Kala Pharmaceut...
Karyopharm Ther...
Carna Bioscienc...
Boston Pharmace...
Vita Data Scien...
Radius Health
Missing a competitor? Contribute!?

Acer Therapeutics Inc. (Nasdaq: ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need. Founded in 2013, Acer completed its Initial Public Offering in 2017, has raised $87M to date, and has rapidly built a diverse portfolio of product candidates. Our pipeline includes three clinical-stage candidates: EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCD) and Maple Syrup Urine Disease (MSUD); and osanetant for the treatment of various neuroendocrine disorders. On December 26, 2018 the U.S. Food and Drug Administration (FDA) accepted for review Acer's New Drug Application (NDA) for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed COL3A1 mutation. The FDA also granted a priority review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 25, 2019. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Acer's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. Acer has a strong company culture and is committed to creating and maintaining an environment that values individual rights, hard work, fosters creativity, and promotes success. The Company is growing rapidly and is fueled by the talent and expertise of our employees, driven by the commitment to treating patients with critical unmet medical needs.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Executive Contacts

Jason KneelandVP Finance, ControllerEmail Available
Will AndrewsChief Medical OfficerEmail Available
Jim DeNikeExecutive Director, Investor Relations
Kristin MulreadyVice President, Program & Alliance Management
Eric VanVactorDirector Of Manufacturing
Darren AllenderDirector, Commercial OperationsEmail Available
Srinivas TetaliVice President Medical Affairs
Don JosephChief Legal OfficerEmail Available
Terrie BurrellVice President, Clinical Science
Stacey BainVice President Clinical Operations

Acer Therapeutics News

09/03/2019 - Acer Therapeutics Reports Second Quarter 2019 Financial ...

13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development ...

09/05/2019 - Acer Therapeutics: Undervalued With A Free Call Option On ...

Acer Therapeutics Inc. (NASDAQ: ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, ...

09/03/2019 - Zacks Investment Research Downgrades Acer Therapeutics ...

Acer Therapeutics (NASDAQ:ACER) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report ...

Acer Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-05-11$8.2MBTVM Life Science Venture VIIArticle
2017-12-18$11.0MUndisclosedWilliam Blair & Company, L.L.C.Article

Acer Therapeutics Executive Hires

2017-10-06William AndrewsChief Medical OfficerArticle
2018-02-06Terrie KellmeyerVice President, Clinical ScienceArticle
2018-12-18Salma JuttChief Commercial OfficerArticle